Drug firm Zydus Cadila said it has received the approval from the Drugs Controller General of India (DCGI) to start phase 3 clinical trials with its biological therapy PegiHep in COVID-19 patients.The trials, which will commence in December, will be conducted on 250 patients across 20-25 centres in India, according to the filing.
Drug firm Zydus Cadila said it has received the approval from the Drugs Controller General of India (DCGI) to start phase 3 clinical trials with its biological therapy PegiHep in COVID-19 patients.The trials, which will commence in December, will be conducted on 250 patients across 20-25 centres in India, according to the filing.
